Want to see TRLV full AI Analyst Report?
TRLV Stock Chart & Stats
$9.47
-$0.22(-4.11%)
At close: 4:00 PM EST
$9.47
-$0.22(-4.11%)
Day’s Range― - ―
52-Week Range$4.62 - $13.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.50M
Market Cap
$2.14B
Enterprise Value$2.14K
Total Cash (Recent Filing)$325.42M
Total Debt (Recent Filing)$260.61M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 11, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding170,158,920
10 Day Avg. Volume674,219
30 Day Avg. Volume1,496,090
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.43
Price to Sales (P/S)1.41
P/FCF Ratio7.83
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.81Price Target Upside88.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.5
Revenue Forecast (FY)$1.01B
Bulls Say, Bears Say
Bulls Say
Cash FlowTrulieve generated significant operating cash flow and maintained a strong cash balance.
EBITDA PerformanceTrulieve's EBITDA margins continue to outperform expectations, with recent results coming in ahead of forecasts.
Revenue GrowthGuidance indicates a projected increase in revenues for the next quarter.
Bears Say
Revenue DeclineGuidance for Q3 is for revenues to decline mid-single digits due to typical seasonal impact.
Trulieve Cannabis News
TRLV FAQ
What was Trulieve Cannabis’s price range in the past 12 months?
Trulieve Cannabis lowest stock price was $4.62 and its highest was $13.28 in the past 12 months.
What is Trulieve Cannabis’s market cap?
Trulieve Cannabis’s market cap is $2.14B.
When is Trulieve Cannabis’s upcoming earnings report date?
Trulieve Cannabis’s upcoming earnings report date is Nov 11, 2026 which is in 80 days.
How were Trulieve Cannabis’s earnings last quarter?
Trulieve Cannabis released its earnings results on Aug 07, 2026. The company reported -$2.11 earnings per share for the quarter, missing the consensus estimate of $0.086 by -$2.196.
Is Trulieve Cannabis overvalued?
According to Wall Street analysts Trulieve Cannabis’s price is currently Undervalued.
Does Trulieve Cannabis pay dividends?
Trulieve Cannabis does not currently pay dividends.
What is Trulieve Cannabis’s EPS estimate?
Trulieve Cannabis’s EPS estimate is 0.09.
How many shares outstanding does Trulieve Cannabis have?
Trulieve Cannabis has 170,158,920 shares outstanding.
What happened to Trulieve Cannabis’s price movement after its last earnings report?
Trulieve Cannabis reported an EPS of -$2.11 in its last earnings report, missing expectations of $0.086. Following the earnings report the stock price went down -2.778%.
Which hedge fund is a major shareholder of Trulieve Cannabis?
Currently, no hedge funds are holding shares in TRLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Trulieve Cannabis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.81 (88.09% Upside)
$17.81 (88.09% Upside)
Blogger Sentiment
Bullish
TRLV Sentiment 73%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
84.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.90%
Trailing 12-Months
Company Description
Trulieve Cannabis
Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.
TRLV Company Deck
TRLV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated multiple substantial strategic and operational wins — uplisting to the NYSE, federal rescheduling benefits (including 280E relief), strong margins (60% gross, 63% medical-only), $98M adjusted EBITDA (36% margin), $53M operating cash flow, and clear near-term growth catalysts in Georgia and Texas. These positives were tempered by a large, non-recurring $407M deconsolidation charge related to Harvest that produced a GAAP net loss, ongoing tax uncertainty tied to 280E (UTP and interest), temporary supply constraints in Georgia, and guidance that Q3 revenue will be flat versus Q2 medical-only. On balance, the operational performance, balance sheet strength, regulatory tailwinds, and strategic growth opportunities outweigh the one-time accounting and transitional challenges discussed on the call.View all TRLV earnings summariesTRLV Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$17.81
▲(88.09% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Jushi Holdings
―
Curaleaf Holdings
―
Green Thumb Industries
―
Cresco Labs
―
Verano Holdings
―









